AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Multicenter Cohort Study of AAV in Hunan of China

Recruitingn/aAges any - anyAllXiangya Hospital of Central South University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA๏ผ‰-associated vasculitis (AAV) progression and its association with adverse consequences. It will enroll approximately 500 AAV patients in Hunan province of China and follow-up for at least 5 years. Demographic characteristics, clinical and laboratory data will be collected at baseline and every follow-up. The principal clinical outcomes of the study consist of end stage renal disease (ESRD) and death.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Fulfill 2012 criteria of ANCA associated vasculitis and agree to sign informed consent Exclusion Criteria: * Do not agree to sign informed consent
๐Ÿ’Š

What it tests

  • No Intervention
๐Ÿ“

Where

1 site
Xiangya hospital
Changsha, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy